enkephalin, leucine has been researched along with tp 7 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeva, LN; Andryushchenko, AV; Gabaeva, MV; Grivennikov, IA; Ivanov, SV; Kost, NV; Myasoedov, NF; Smulevich, AB; Yu Sokolov, O; Zolotarev, YA; Zozulya, AA | 1 |
| Kost, NV; Meshavkin, VK; Sokolov, OY; Zozulya, AA | 1 |
| Andriushenko, AV; Gabaeva, MV; Kost, NV; Miasoedov, NF; Neznamov, GG; Serebriakova, EV; Seredenin, SB; Siranchieva, OA; Siuniakov, SA; Siuniakov, TS; Smulevich, AB; Sokolov, OIu; Telesheva, ES; Zozulia, AA | 1 |
1 trial(s) available for enkephalin, leucine and tp 7
| Article | Year |
|---|---|
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Biomarkers; Dose-Response Relationship, Drug; Enkephalins; Female; Follow-Up Studies; Humans; Male; Medazepam; Middle Aged; Neurasthenia; Oligopeptides; Psychometrics; Severity of Illness Index; Treatment Outcome | 2008 |
2 other study(ies) available for enkephalin, leucine and tp 7
| Article | Year |
|---|---|
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.
Topics: Anti-Anxiety Agents; Enkephalins; Humans; Neprilysin; Neurotic Disorders; Oligopeptides; Phobic Disorders | 2001 |
Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions.
Topics: Animals; Anti-Anxiety Agents; Enkephalin, Leucine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Motor Activity; Neprilysin; Oligopeptides; Phenotype; Stress, Physiological | 2002 |